BioTime developed a GMP banking and production platform and provides clinical/development expertise involving Genentech and Roche.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioTime developed a GMP banking and production platform and provides clinical/development expertise involving Genentech and Roche.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BioTime
company
Nothing else this week.
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.
- BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.
Coverage
Newest first; wire copies grouped- GuruFocus.comLineage Cell Therapeutics Inc (LCTX) Q2 2025 Earnings Call Highlights: Strategic Partnerships ... Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the f